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The rate of invasive group B Streptococcus (GBS) infections is steadily increasing,
particularly in older persons and in adults with diabetes and other comorbidities.
This population includes persons with a foreign body (e.g., who have undergone
arthroplasty). In a rat tissue cage model, we evaluated the efficacy of adjunctive
gentamicin (GEN) administered systemically (5 mg/kg body weight) every 24 h, or
locally (12.5 mg/L tissue cage concentration) every 24 or 72 h, in combination with
penicillin (PEN) administered systemically (250,000 IU/kg body weight three times per
day). The efficacy was evaluated on two different sessile forms of GBS: transition (i.e.,
in between planktonic and biofilm) and biofilm. After 3 days of treatment, the mean
bacterial load reduction of transition-form GBS was greater in all PEN–GEN combination
groups than in the PEN monotherapy group (P ≤ 0.03). The 6-day regimen decreased
the bacterial load significantly in comparison to the 3-day regimen, irrespective of growth
form and adjunctive GEN (P < 0.01). After 6 days of treatment, the mean reduction in
transition-form GBS was greater with PEN plus GEN administered locally every 24 h
than with PEN monotherapy (P = 0.03). These results were not confirmed with biofilm
GBS. The difference in mean bacterial load reduction between all PEN–GEN and PEN
monotherapy groups was <100 CFU/mL. Hence, synergy criteria were not fulfilled.
Adjunctive systemic GEN consists of potential side effects and showed poor efficacy
in this study. Combining systemic PEN and local GEN has a potential application in the
treatment of streptococcal implant-associated infections.
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INTRODUCTION
The rate of invasive group B Streptococcus (GBS, Streptococcus agalactiae) disease in non-pregnant
adults has substantially increased in the past decade (Skoff et al., 2009; Ballard et al., 2016). In
particular, older persons and adults with diabetes and other substantial comorbidities are at risk
(Sendi et al., 2008; Skoff et al., 2009). For GBS periprosthetic joint infection (PJI) and infective
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endocarditis, a combination therapy of penicillin G (PEN)
plus gentamicin (GEN) for the first 2 weeks followed by PEN
monotherapy is recommended (Zimmerli et al., 2004; Westling
et al., 2007). The rationale for this combination therapy is a
postulated synergistic effect (Schauf et al., 1976; Deveikis et al.,
1977; Cooper et al., 1979; Baker et al., 1981). In contrast to
these study findings, the results of our recent experiments did
not confirm a synergistic effect with planktonic GBS (Ruppen
et al., 2016b, 2017a). In view of the potential nephrotoxicity
of aminoglycosides and the increasing elderly population at
risk for invasive GBS disease, the decision to administer or
withhold aminoglycosides is of clinical relevance. Given the
fact that in PJI, sessile forms of bacteria are involved, we
evaluated whether this combination therapy is active against
biofilm GBS in vitro (Ruppen et al., 2016a). Although a
synergistic effect was seen in two of four tested GBS isolates, the
results indicated that the required GEN concentration cannot
be achieved in an extravascular compartment with systemic
administration (Ruppen et al., 2016a). The translation of these
results into in vivo conditions requires caution. The effect of
concentration fluctuation is not reflected in vitro, since fixed
antibiotic concentrations are used. In addition, in infections
affecting tissues or biological fluids, the pH can be acidic, and
this milieu increases the minimum inhibitory concentrations
(MICs) of aminoglycosides for Gram-positive cocci (Baudoux
et al., 2007). Therefore, the objective for the present in vivo study
was to test the synergistic effect of GEN – administered either
systemically or locally – as an adjunct to systemic PEN treatment
in an experimental model of GBS foreign-body infection. In
consideration that elderly people are at risk for both invasive GBS
and adverse events from antimicrobial treatment, we focused on
aged animals in the model.
MATERIALS AND METHODS
Ethics Statement
The Animal Care and Experimentation Committee of the Canton
of Bern, Switzerland, approved this study (License and Reference
No. BE 80/16). According to the Swiss national guidelines for
the performance of animal experiments, a recovery phase must
follow an intervention phase (e.g., day or light cycle for 12 h).
During the recovery phase, neither diagnostic nor therapeutic
interventions are allowed.
GBS Strain
The isolate was obtained from a patient with PJI (BE07-1b) and
characterized previously (serotype Ib, multilocus sequence type
8, PEN MIC 0.032 mg/L, GEN MIC 24 mg/L) (Ruppen et al.,
2016a,b, 2017a).
Animals
Female retired breeder Wistar Han rats purchased from
Charles River Laboratories (Sulzfeld, Germany) were used in all
experiments. Median weights of animals are indicated in the
corresponding sections below. The rats were housed in groups
of four that had previous surgical procedures and singly after
the operation to prevent implant removal due to social behavior.
They were housed in individually ventilated cages with unlimited
access to food and water. Room temperature was maintained
(22± 2◦C) with a 12-h light/dark cycle.
Tissue Cage Infection Model
Tissue cages were implanted in animals, as reported previously
(Zimmerli et al., 1982; Murillo et al., 2006). In brief, two
teflon tissue cages with 150 spaced perforations of 1-mm
diameter (Mecanizados del Besos, Badalona, Spain) were
subcutaneously (s.c.) implanted. Each tissue cage contained
two polymethylmethacrylate coverslips (Mecanizados del Besos,
Badalona, Spain) (see Supplementary Figure S1). Eighteen days
after implantation of tissue cages (i.e., recovery time after
surgery), tissue cage fluid (TCF) was examined for sterility (see
Supplementary Figure S2). Upon documentation of no bacterial
growth in TCF, pharmacokinetic (PK), and GBS infection studies
were started.
PK Studies
The median weights of animals included in the PK studies were
370 g (number of animals: 21 and weight range: 275–548 g).
Antibiotic concentrations were measured in animals without
introducing an infection. At each measured time point, three
samples from three different animals were obtained. The time
interval in obtaining two consecutive TCF samples was never
<6 h in any animals (to minimize their stress). The PK study
included three treatment regimens:
(i) PEN 150 mg/kg (250,000 IU/kg) body weight (BW) given
three times systemically (i.e., s.c.) with a 4-h interval
between each administration (number of animals: 9). The
dose was chosen on the basis of a previous PEN PK
study in rats (Gavalda et al., 1997). The administration
was restricted to three doses because of the 12-h-cycle
intervention restriction (see section “Ethics Statement”).
(ii) GEN 5 mg/kg BW s.c. as a single dose (number of
animals: 9).
(iii) GEN locally, final tissue cage concentration 12.5 mg/L
(tissue cage volume 2.5 mL, injection volume 0.2 mL with
GEN 156 mg/L; number of animals: 3).
The rationale for selecting these PEN and GEN doses was
based on reported levels of corresponding antibiotics found in
human serum (Kim and Bayer, 1985; Kim, 1987; Gavalda et al.,
1997) and our previous in vitro study with biofilm GBS (Ruppen
et al., 2016a). In animals treated with regimens (i) and (ii), TCF
samples were obtained at the following time points: 0.5, 1, 4,
6, 8, 12, and 24 h. After 24 h, animals were euthanized and a
serum sample obtained. In animals treated with local GEN (group
iii), TCF and serum samples were obtained at the following time
points: 24, 48, and 72 h. Thereafter, animals were euthanized (see
Supplementary Figure S2).
GBS Infection Study
The study plan included 32 animals (median weight: 359.5 g
and range: 268–552 g). Thirty-one rats (one loss after
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anesthesia) were infected with an inoculum of 2–5 × 104
CFU/mL in 0.1 ml injected into the tissue cage. Four days
later, TCF was extracted to quantify the bacterial load in
the tissue cage (i.e., pretreatment colony count) (Figure 2).
Thereafter, antimicrobial treatment was started. The systemic
antimicrobial treatment duration was either 3 or 6 days (see
Supplementary Figure S2). The compound in the negative
control group consisted of 0.9% sodium chloride (Sintetica,
Mendrisio, Switzerland). Because acidic pH can increase
MICs of aminoglycosides for Gram-positive cocci (Baudoux
et al., 2007), the pH in TCF was measured at days 1,
3, and 6 with indicator stripes (Macherey-Nagel, Düren,
Germany).
Antimicrobial Agents and Serum
Concentration Measurements
PEN (benzylpenicillin-sodium, Grünenthal Pharma AG, Mitlödi,
Switzerland) and GEN (Hexal AG, Holzkirchen, Germany)
were supplied from the clinical pharmacy of the University
Hospital (Bern, Switzerland). Prior to administration, antibiotic
concentrations in original vials were diluted until they reached
the targeted value and were then measured, as described
previously (Ruppen et al., 2016b). Antibiotic concentrations of
PEN and GEN in serum and TCF samples obtained from animals
were measured via high-performance liquid chromatography-
mass spectrometry(Ruppen et al., 2016b).
Systemic Treatment and Combination
Thereof
For comparative analyses, the efficacy of PEN monotherapy was
evaluated with that of PEN–GEN combination therapy. PEN
monotherapy consisted of PEN G 150 mg/kg BW s.c. as three
doses daily (every 4 h followed by an antibiotic-free interval of
12 h). The administration was restricted to three doses per day
because of the 12-h-cycle intervention restriction (see section
“Ethics Statement”). The combination therapy consisted of PEN
as described for monotherapy plus GEN 5 mg/kg BW s.c. as one
dose per day (see Supplementary Figure S2).
Combination of Systemic PEN Plus Local
GEN Treatment
These combinations consisted of PEN, as described earlier, plus
GEN 12.5 mg/L injected into the tissue cage as one dose either
every 72 h or every 24 h. The former regimen was evaluated
after 3 and 6 days, the latter only after 6 days (see Supplementary
Figure S2).
Read-Out and Synergy Definition
The efficacy of the treatment regimen on sessile bacteria
in transition form was evaluated in samples obtained from
TCF after 3 and 6 days of treatment. Samples were plated
on Columbia sheep blood agar and incubated at 37◦C in
5% CO2 for 24 h for colony counting. The efficacy of the
treatment regimen on sessile bacteria in biofilm was evaluated
in samples obtained from coverslips after 3 and 6 days of
treatment. Animals were euthanized and coverslips removed
from tissue cages and subjected to trypsin and sonication, as
described previously (Murillo et al., 2006; Ruppen et al., 2016a).
Dislodged bacteria were then plated on Columbia sheep blood
agar and incubated at 37◦C in 5% CO2 for 24 h for colony
counting.
The synergy definition was modified according to the
experimental setting and defined as a ≥100-fold (≥2 logs)
increase in killing after 3 and 6 days of treatment (as measured by
colony counts [CFU/mL]) with the PEN plus GEN combination
therapy in comparison with the PEN monotherapy.
Graphical representation and statistical analyses were
performed with GraphPad Prism 7.01 (GraphPad Software, Inc.,
San Diego, CA, United States). A P-value of < 0.05 calculated by
the Mann–Whitney test was considered significant.
The efficacy of antibiotics was evaluated on two bacterial
growth forms. The first form was obtained from TCF and these
bacteria were regarded as GBS in a “transition form” from a
planktonic to a biofilm state and vice versa (see Supplementary
Figure S1). The second form was obtained from sonicated fluid
after coverslips were sonicated and treated with trypsin. These
bacteria were regarded as “biofilm bacteria” (see Supplementary
Figure S1).
RESULTS
PK Studies
The systematically administered antimicrobials rapidly
penetrated into the tissue cage. Thirty minutes after
administration, the median PEN and GEN concentrations were
15.49 and 5.97 mg/L (range: 2.04–42.74 and 3.99–8.33 mg/L),
respectively. The PKs of PEN and GEN concentrations in the
TCF are illustrated in Figures 1A,C. Because of obtaining
repetitive TCF samples (Figure 1A), measurement of penicillin
in TCF at the 24-h time point was possible in only four
animals; serum concentrations corresponding to the TCF
sample are displayed in Figure 1B. Twelve hours after the
last dose (i.e., 24 h after the first dose), the median PEN
concentration in the TCF dropped to 0.765 mg/L (range:
0.03–2.01), but was still above the PEN MIC of the GBS
isolate (0.032 mg/L). At 24 h, the corresponding median
PEN concentration in serum was 0.155 mg/L (range: 0.11–
0.23) (Figure 1B). Twenty-four hours after a single dose of
systemically administered GEN (5 mg/kg BW), the median
concentration in the TCF was 0.11 mg/L (range: 0–0.62), while
it was undetectable in serum (Figure 1D). At 24, 48, and 72 h
after a single dose of locally administered GEN (12.5 mg/L),
the TCF concentration dropped to ≤1 mg/L and was not
measurable in the serum at any corresponding time points
(Figure 1E).
GBS Infection Study
Four of 31 animals were excluded from the results because of
contamination of the tissue cage with additional microorganisms.
Hence, the results for 27 animals were available for the read-out.
None of the animals developed sepsis or died from infection.
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FIGURE 1 | Pharmacokinetics of penicillin G (PEN) and gentamicin (GEN) in tissue cage fluid (TCF) and serum. The numbers in brackets reflect the total number of
animals used for the PK study. At each measured time point, three samples from three different animals were obtained. The time interval in obtaining two consecutive
TCF samples was never <6 h in any animals (to minimize their stress). Results are presented as median ± range. (A) PEN 150 mg/kg body weight (BW)
subcutaneously (s.c.) given three times (every 4 h). (B) PEN 150 mg/kg BW s.c. given three times (every 4 h) and measured in TCF and serum after 24 h. (C) GEN
5 mg/kg BW s.c. given once daily. (D) GEN 5 mg/kg BW s.c. given once daily and measured in TCF and serum after 24 h. (E) GEN 12.5 mg/L applied locally once
and the concentration measured in TCF and serum after 24, 48, and 72 h.
pH in the TCF During the Infection Study
At days 1, 3, and 6, the pH in the TCF remained stable at >6 and
<7.5, indicating that the pH of the milieu had no considerable
effect on the GEN MIC of GBS.
Effect of Antimicrobial Treatment on Sessile Bacteria
in Transition Form
Systemic therapy, 3 days of treatment (Figure 2A)
The mean bacterial load was significantly lower in the
PEN–GEN group (4.9 [SD ± 5.7] × 105 CFU/mL) than
it was in the corresponding PEN monotherapy group
(2.3 [± 3.5] × 106 CFU/mL) (P = 0.031). Because the
difference was <100 CFU/mL, criteria for synergism were
not fulfilled.
Systemic therapy, 6 days of treatment (Figure 2B)
The bacterial load was significantly lower after 6 days of PEN
monotherapy (2.2 [± 4.4] × 105 CFU/mL) than it was after all
3-day treatment regimens (P = 0.0007). Within the groups with
6 days of treatment, the difference in the mean bacterial load with
PEN monotherapy was not significant in comparison to that of
PEN–GEN combination therapy (0.9 [± 1.2]× 104 CFU/mL).
Systemic PEN plus local GEN therapy, 3 days of treatment
(Figure 2C)
The combination of PEN plus local GEN treatment showed
a significant reduction in the mean bacterial load to 4.9
[± 7.1] × 105 CFU/mL (one GEN dose every 72 h) and
1.4 [± 1.0] × 105 CFU/mL (one GEN dose every 24 h),
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FIGURE 2 | Bacteria in transition form measured in TCF after 3 and 6 days of treatment. The numbers in brackets below the x-axis reflect the number of animals
(each animal with two tissue cages). Each dot reflects one sample. (A) GBS CFU/mL after 3 days of systemic (sys) penicillin (PEN) and penicillin plus gentamicin
(GEN) treatment. (B) GBS CFU/mL after 6 days of systemic PEN and PEN plus GEN treatment. (C) GBS CFU/mL after 3 days of systemic PEN and local GEN
treatment. (D) GBS CFU/mL after 3 days of systemic PEN and local GEN treatment. Data represent mean ± standard deviation (SD). Statistical analysis was
calculated with the Mann–Whitney test, representing a value of ∗P < 0.05 and P < 0.001.
respectively, in comparison to that of systemic PEN monotherapy
(2.3 [± 3.5] × 106 CFU/mL) (P = 0.03 and P < 0.01,
respectively).
Systemic PEN plus local GEN therapy, 6 days of treatment
(Figure 2D)
When local GEN was administered every 24 h, the mean
bacterial load reduction was significant in the combination group
in comparison to that in the PEN monotherapy group (5.8
[± 2.9] × 103 CFU/mL versus 2.2 [± 4.4] × 105 CFU/mL)
(P = 0.03). The difference was not significant if GEN was
administered every 72 h.
Effect of Antimicrobial Treatment on Sessile Bacteria
in Biofilm
Systemic therapy, 3 days of treatment (Figure 3A)
There was no considerable difference in bacterial load when
PEN monotherapy was compared with systemic PEN–GEN
combination therapy.
Systemic therapy, 6 days of treatment (Figure 3B)
The mean bacterial load was significantly reduced after 6 days
of PEN monotherapy (0.8 [± 1.4] × 104 CFU/mL) in
comparison with that after 3-day treatment with monotherapy
(2.6 [± 4.1] × 105 CFU/mL) (P < 0.01). However, there was no
significant difference in bacterial load when PEN monotherapy
was compared with systemic PEN–GEN combination therapy
after 6 days.
Systemic PEN plus local GEN therapy, 3 days of treatment
(Figure 3C)
No significant difference in bacterial load was seen when PEN
monotherapy was compared with PEN plus single-dose local
GEN (i.e., one dose for 72 h) combination therapy.
Systemic PEN plus local GEN therapy, 6 days of treatment
(Figure 3D)
The most pronounced reduction in the mean bacterial load to
7.4 [± 8.6] × 102 CFU/mL (i.e., 1.6 [± 0.9] × 106 CFU/mL
reduction in comparison to that in the control group) was
observed with PEN plus one dose of local GEN given every day.
Interestingly, the mean bacterial load with PEN monotherapy
was significantly lower than that with PEN plus local GEN
combination therapy (one dose every 72 h). There was a
considerable range in sample results (1 × 102–5 × 104 CFU/mL
PEN monotherapy versus 5 × 103–1 × 106 CFU/mL PEN plus
local GEN every 72 h).
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FIGURE 3 | Bacteria in biofilm recovered from coverslips after 3 and 6 days of treatment. The numbers in brackets below the x-axis reflect the number of animals
(each animal with two tissue cages). Each dot reflects one sample. (A) GBS CFU/mL after 3 days of systemic (sys) penicillin (PEN) and penicillin plus gentamicin
(GEN) treatment. (B) GBS CFU/mL after 6 days of systemic PEN and PEN plus GEN treatment. (C) GBS CFU/mL after 3 days of systemic PEN and local GEN
treatment. (D) GBS CFU/mL after 6 days of systemic PEN and local GEN treatment. Data represent mean ± SD. Statistical analysis was calculated with the
Mann–Whitney test, representing a value of ∗P < 0.05.
DISCUSSION
In GBS foreign-body infections in humans, PEN is commonly
administered intravenously every 4 to 6 h (e.g., 18–24
million U/day) (Zimmerli et al., 2004). There are, however,
few PK studies on PEN concentration in extravascular
compartments (e.g., synovial fluid or bone). The mean PEN
serum concentration is approximately 80 mg/L 30 min after
intramuscular administration and 3 mg/L 4 h after completion
of intravenous administration of 5 million IU PEN (Plaut et al.,
1969; Geddes and Gould, 2010; Grünenthal Pharma AG, 2012).
The elimination half-time of PEN is 30 min –in both humans
and rats (Gavalda et al., 1997) – and the penetration in synovial
fluid is reported to be ≥50% of serum levels (Parker and Schmid,
1971; Grünenthal Pharma AG, 2012). Hence, from mathematical
extrapolation, the expected PEN concentration in synovial fluid
is approximately 1.5 mg/L 4 h after completion of intravenous
administration of 5 million IU PEN. The recommended dosage
for adjunctive GEN treatment in humans is 3 mg/kg BW given
intravenously, leading to a serum peak concentration of 12 to
14 mg/L. GEN penetrates well to synovial fluid (i.e., >50% of
serum levels) (Dee and Kozin, 1977). It has an average serum
elimination half-time of 2.5 h in humans and <1 h in rats
(Tran Ba Huy et al., 1986). In analogy to the above-mentioned
extrapolation, approximately 6 to 7 mg/L peak concentration
and <1 mg/L after 24 h is estimated in synovial fluid. Similar
PEN and GEN values were targeted in our in vivo model,
though it is unknown whether the antibiotic concentration
in synovial fluid corresponds to that in TCF. In addition, the
mathematical extrapolation may be imprecise given the many
confounders in a biological system and the different routes
of administration. However, the PK results in the TCF reflect
those in an extravascular compartment, and the drug levels after
24 h in both serum and TCF were within the expected range
(Figures 1A–E).
Significant bacterial growth was detected in samples cultured
from TCF and coverslips despite PEN concentrations being
above the GBS MIC during the entire treatment period. This
points toward the foreign-body infection treatment concept
of considering the minimal biofilm eradication concentration
(MBEC), which is substantially higher than the PEN MIC
(Ruppen et al., 2016a). We analyzed two forms of sessile bacteria
because biofilm biology is regarded as a continuum of various
growth phases (i.e., from planktonic to stationary and vice versa)
(see Supplementary Figure S1). The reduction in bacterial load
was minor after 3 days of treatment, irrespective of growth
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form and treatment regimen. At this measured time point, we
observed – in line with our previous in vitro results (Ruppen
et al., 2016b) – a significant difference in killing of transition-
form GBS between PEN monotherapy and systemic PEN–GEN
combination therapy, without fulfilling the criteria for synergism
(Figure 2A). The difference between PEN monotherapy and
systemic PEN–GEN combination therapy was not observed for
assays with biofilm bacteria and not after 6 days of treatment.
Six days of PEN treatment was significantly more efficient than
3 days of PEN treatment in reducing the bacterial load, but it did
not cure the infection, irrespective of adjunctive GEN treatment.
This confirms that short treatment duration is insufficient for
foreign-body infections. It also indicates that prolonged PEN
treatment may have an effect on biofilm bacteria (Figure 3D),
even when MBECs are higher than MICs by a considerable
magnitude (Ruppen et al., 2016b). Drug accumulation in the
tissue cage may have contributed to the bacterial killing. However,
we did not assess PEN concentration accumulation in TCF after
6 days. Synergism was not observed in any of the assays in
which PEN monotherapy was compared with systemic PEN–
GEN combination therapy. We have previously outlined that,
with systemic administration, the required GEN concentration
in the extravascular compartment may not be reached (Ruppen
et al., 2016a). Indeed, 30 min after systemic administration, GEN
concentrations in TCF ranged from 4 to 8 mg/L and dropped
rapidly thereafter. This PK pattern was also seen when the same
formulation with a concentration of 12.5 mg/L was administered
locally every 72 h. A slow-release drug formulation with high
GEN concentration for local treatment may be a better treatment
option (Humphrey et al., 1998). In line with this reasoning and
the results found in our in vitro studies with biofilm GBS (Ruppen
et al., 2016a), the most pronounced killing for biofilm bacteria
was observed when systemic PEN and local high-dose GEN was
used every 24 h for a prolonged treatment period (Figure 3D).
The mechanism of action of adjunctive GEN against non-
replicating bacteria is poorly understood. It is possible that –
at least in part – the GEN MIC, and hence the GEN MBEC,
play a more important role than they do in planktonic bacteria
(Ruppen et al., 2017b). In four biofilm GBS with GEN MICs
ranging from 8 to 32 mg/L and MBECs from 8 to 64 mg/L, in vitro
exposure to GEN at a concentration of 4 mg/L had little effect on
bacterial killing (Ruppen et al., 2016a). Similarly, and together
with the rapid drop in drug levels observed in our TCF, it is
possible that the GEN MIC, minimal bactericidal concentration
(MBC), or MBEC increases with exposure to insufficient GEN
concentration (i.e., development of tolerance). This theory is,
however, challenging to prove since methods of susceptibility
testing and MIC cut-off values for GEN susceptibility have not
been established. In addition, testing must be performed with
GBS dislodged from coverslips after sonication (i.e., returning
the biofilm to planktonic bacteria), making the interpretation
of results difficult. Notably, our hypothesis was tested in vivo
with only one GBS isolate. Another testing limitation involves
the interpretation of PK studies in a condition without infection
and a PEN-dosing-free interval of 12 h due to ethical restrictions.
Despite this, PK results indicated that PEN levels were above
the MIC during the entire experimental period. GEN dosing
was extrapolated from serum studies in humans despite a faster
plasma elimination half-time in rats, although the GEN peak
serum level (Cmax) is comparable between rats and humans (Tran
Ba Huy et al., 1986). The criteria for the definition of synergism
are arbitrary. Nonetheless, no impressive difference was seen
when we compared the bacterial loads after PEN treatment with
those after PEN–GEN treatment, irrespective of this definition.
CONCLUSION
Our investigations in an experimental model of GBS foreign-
body infection did not show considerable added value of
systemically administered GEN as an adjunct to PEN for killing
two different growth forms of sessile GBS. A possible explanation
for this observation may be – in comparison to serum – the
low GEN concentration in the extravascular compartment. The
translation of these findings into clinical practice requires further
studies with a higher number of strains. If GEN is used, the results
of this study point toward the combination of systemic PEN plus
local high-dose GEN in a slow-release drug formulation. This
combination has a potential application in orthopedic device-
associated infections caused by GBS.
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